MOLECULAR CANCER THERAPEUTICS
Scope & Guideline
Exploring the molecular mechanisms behind cancer therapies.
Introduction
Aims and Scopes
- Novel Therapeutic Agents:
The journal features research on newly developed therapeutic agents, including small molecules, antibodies, and antibody-drug conjugates, aimed at targeting specific cancer types and overcoming resistance mechanisms. - Combination Therapies:
A significant focus is on combination therapies, which explore the synergistic effects of different treatment modalities, such as chemotherapy, immunotherapy, and targeted therapies, to enhance efficacy and reduce resistance. - Mechanisms of Drug Resistance:
Research delves into the molecular mechanisms that contribute to drug resistance in cancer, providing insights that can guide the development of new therapeutic strategies and improve treatment outcomes. - Biomarker Identification and Validation:
The identification and validation of biomarkers that predict response to therapies are crucial aspects of the journal, enhancing personalized medicine approaches in oncology. - Preclinical and Clinical Studies:
The journal publishes findings from both preclinical models and clinical trials, bridging the gap between laboratory research and patient care, thus facilitating the translation of scientific discoveries into therapeutic applications. - Tumor Microenvironment Interactions:
Research on the interactions between tumors and their microenvironment is emphasized, particularly how these interactions influence treatment response and resistance.
Trending and Emerging
- Targeted Therapy Innovations:
There is a significant trend towards the development of highly selective targeted therapies, including PROTACs and small-molecule inhibitors that address specific mutations and pathways in cancer, thereby enhancing treatment precision. - Immunotherapy and Immune Modulation:
The exploration of immunotherapy continues to gain momentum, with a focus on innovative approaches that enhance the immune response against tumors, including immune checkpoint inhibitors and T-cell engagers. - Biomarker-Driven Treatment Approaches:
Emerging research emphasizes the importance of biomarker-driven approaches to personalize cancer treatment, allowing for tailored therapies based on individual patient profiles and tumor characteristics. - Nanotechnology in Cancer Therapy:
The use of nanotechnology for drug delivery systems is on the rise, facilitating targeted and effective delivery of therapeutics to tumor sites while minimizing systemic toxicity. - Exploration of Tumor Microenvironment Dynamics:
Research increasingly focuses on understanding the tumor microenvironment's role in cancer progression and treatment response, leading to innovative strategies that target both tumor cells and their surrounding stroma. - Combination of Targeted Therapies with Immunotherapy:
There is a growing interest in the synergistic potential of combining targeted therapies with immunotherapies, which aims to enhance overall treatment efficacy and address resistance mechanisms.
Declining or Waning
- Traditional Chemotherapy Approaches:
While traditional chemotherapy remains a cornerstone in cancer treatment, research focusing solely on these approaches is declining as the field shifts towards targeted therapies and immunotherapies that offer more personalized treatment options. - Single-Agent Studies:
There is a noticeable decrease in studies investigating single-agent therapies, as the trend moves towards exploring combination therapies that leverage synergistic effects for improved outcomes. - Basic Science Without Therapeutic Application:
Research that focuses primarily on basic cancer biology without direct therapeutic implications or translational relevance is becoming less prevalent, as emphasis grows on studies that can lead to practical treatments.
Similar Journals
CANCER BIOLOGY & THERAPY
Empowering breakthroughs in cancer biology and therapy.CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.
Cancer Research Communications
Empowering global collaboration in cancer research.Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Unveiling the future of oncology through rigorous pharmacological research.Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.
Cancer Reports
Fostering collaboration in the fight against cancer.Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.
Oncogenesis
Advancing cancer research for a healthier tomorrow.Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.
Molecular & Cellular Oncology
Innovating therapeutic interventions for a brighter future.Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.
ONCOGENE
Advancing Cancer Research Through Innovative InsightsONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.
INTERNATIONAL JOURNAL OF ONCOLOGY
Pioneering innovative practices in cancer treatment.INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Connecting Research, Treatment, and Future Directions in OncologyBIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.
ANTICANCER RESEARCH
Pioneering Research for a Cancer-Free FutureANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.